Listeria monocytogenes has been exploited previously as a vaccine vector for the delivery of
heterologous proteins such as tumor-specific antigens for active cancer immunotherapy …

As a facultative intracellular bacterium, Listeria monocytogenes has adapted to live within
the cytosol of the host cell. It is actively taken up by antigen-presenting cells through …

Prostate specific antigen (PSA) is a likely immunotherapeutic target antigen for prostate
cancer, the second leading cause of cancer-related death in American men. Previously, we …

The promise of tumor immunotherapy to significantly improve survival in patients who are
refractory to long-standing therapies, such as chemotherapy and radiation, is now being …

Cancer immunotherapy has developed into a field of intense study as aspects of the immune
system involved in the eradication of cancer have become delineated. Listeria …

The intracellular pathogen Listeria monocytogenes represents a promising therapeutic
vector for the delivery of DNA, RNA or protein to cancer cells or to prime immune responses …

The bacterium L. monocytogenes is a proposed vaccine carrier based upon the observation
that this pathogen replicates within the intracytoplasmic environment facilitating delivery of …

Introduction: The development of an effective therapeutic vaccine to induce cancer-specific
immunity remains problematic. Recently, a species of intracellular pathogen known as …

For over a century, inactivated or attenuated bacteria have been employed in the clinic as
immunotherapies to treat cancer, starting with the Coley's vaccines in the 19th century and …

Listeria monocytogenes has recently been exploited as a vector for targeting antigens to the
immune system. In the past year it has been shown to be particularly effective as a tumor …